MedTrace Logo

Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets

NCT02718846 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2016-03-24

No results posted yet for this study

Summary

A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace tablets for patients with Meniere's disease

Conditions

  • Meniere's Disease

Interventions

DRUG

Meniace

6 mg of Meniace tablets were administered 3 times per day after meals

DRUG

Isobide

an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Principal Investigators

  • Won-ho Jeong, Ph.D. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-05-31
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718846 on ClinicalTrials.gov